Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The aim of this phase IV interventional study is to evaluate variation in bone mineral
density and lean and fat body composition in patients with prostate cancer without bone
metastasis, treated with Degarelix. These variations are evaluated at time 0 (before starting
androgen deprivation therapy with Degarelix) and after 12 months of therapy by dual-energy
X-ray absorptiometry (DXA scan).
Phase:
Phase 4
Details
Lead Sponsor:
Azienda Ospedaliera Spedali Civili di Brescia Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia